Sanofi (SNY)
NASDAQ: SNY · Real-Time Price · USD
47.80
-0.22 (-0.46%)
Apr 16, 2026, 10:13 AM EDT - Market open
Sanofi Employees
Sanofi had 74,846 employees as of December 31, 2025. The number of employees decreased by 8,032 or -9.69% compared to the previous year.
Employees
74,846
Change (1Y)
-8,032
Growth (1Y)
-9.69%
Revenue / Employee
$732,842
Profits / Employee
$122,564
Market Cap
115.62B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 74,846 | -8,032 | -9.69% |
| Dec 31, 2024 | 82,878 | -3,210 | -3.73% |
| Dec 31, 2023 | 86,088 | -5,485 | -5.99% |
| Dec 31, 2022 | 91,573 | -3,869 | -4.05% |
| Dec 31, 2021 | 95,442 | -3,970 | -3.99% |
| Dec 31, 2020 | 99,412 | -997 | -0.99% |
| Dec 31, 2019 | 100,409 | -3,817 | -3.66% |
| Dec 31, 2018 | 104,226 | -2,340 | -2.20% |
| Dec 31, 2017 | 106,566 | -293 | -0.27% |
| Dec 31, 2016 | 106,859 | -2,230 | -2.04% |
| Dec 31, 2015 | 109,089 | 1,702 | 1.58% |
| Dec 31, 2014 | 107,387 | -4,741 | -4.23% |
| Dec 31, 2013 | 112,128 | 154 | 0.14% |
| Dec 31, 2012 | 111,974 | -1,745 | -1.53% |
| Dec 31, 2011 | 113,719 | 12,144 | 11.96% |
| Dec 31, 2010 | 101,575 | -3,292 | -3.14% |
| Dec 31, 2009 | 104,867 | 6,654 | 6.78% |
| Dec 31, 2008 | 98,213 | -1,282 | -1.29% |
| Dec 31, 2007 | 99,495 | -794 | -0.79% |
| Dec 31, 2006 | 100,289 | 3,108 | 3.20% |
| Dec 31, 2005 | 97,181 | 742 | 0.77% |
| Dec 31, 2004 | 96,439 | 63,353 | 191.48% |
| Dec 31, 2003 | 33,086 | 650 | 2.00% |
| Dec 31, 2002 | 32,436 | 1,922 | 6.30% |
| Dec 31, 2001 | 30,514 | 1,314 | 4.50% |
| Dec 31, 2000 | 29,200 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 95,100 |
| Novartis AG | 75,267 |
| Pfizer | 75,000 |
| Merck & Co. | 75,000 |
| Novo Nordisk | 69,505 |
| GSK plc | 66,841 |
| AbbVie | 57,000 |
| Bristol-Myers Squibb Company | 32,500 |
SNY News
- 3 days ago - Sanofi (SNY) Gains EU Approval for Dupixent in Young Patients with CSU - GuruFocus
- 3 days ago - Regeneron And Sanofi's Dupixent Gets EC Approval To Treat Children Aged 2-11 Years With CSU - Nasdaq
- 3 days ago - Sanofi (SNY) and Regeneron (REGN) Gain EU Approval for Dupixent in Young Children - GuruFocus
- 3 days ago - Regeneron, Sanofi Secure EU Nod To Expand Dupixent Use In Young Children With CSU - Nasdaq
- 3 days ago - Sanofi: Sanofi and Regeneron's Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria - Finanz Nachrichten
- 3 days ago - Press Release: Sanofi and Regeneron's Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria - GlobeNewsWire
- 3 days ago - Press Release: Sanofi and Regeneron's Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria - Benzinga
- 6 days ago - Sanofi (SNY) Gains Authorization for Nuvaxovid in Canada - GuruFocus